These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30037800)

  • 1. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.
    Jiang YP; Liu BY; Zheng Q; Panuganti S; Chen R; Zhu J; Mishra M; Huang J; Dao-Pick T; Roy S; Zhao X; Lin J; Banik G; Hsi ED; Mandalam R; Junutula JR
    Blood Adv; 2018 Jul; 2(14):1738-1749. PubMed ID: 30037800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
    Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
    Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
    Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
    Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
    Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
    Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
    Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
    Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
    Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
    Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.
    Nielsen CF; van Putten SM; Lund IK; Melander MC; Nørregaard KS; Jürgensen HJ; Reckzeh K; Christensen KR; Ingvarsen SZ; Gårdsvoll H; Jensen KE; Hamerlik P; Engelholm LH; Behrendt N
    Oncotarget; 2017 Jul; 8(27):44605-44624. PubMed ID: 28574834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
    Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
    Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.
    Lo TH; Abadir E; Gasiorowski RE; Kabani K; Ramesh M; Orellana D; Fromm PD; Kupresanin F; Newman E; Cunningham I; Hart DNJ; Silveira PA; Clark GJ
    PLoS One; 2019; 14(5):e0216368. PubMed ID: 31075107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.
    Morsink LM; Walter RB; Ossenkoppele GJ
    Blood Rev; 2019 Mar; 34():26-33. PubMed ID: 30401586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.
    Lu H; Zhou Q; Deshmukh V; Phull H; Ma J; Tardif V; Naik RR; Bouvard C; Zhang Y; Choi S; Lawson BR; Zhu S; Kim CH; Schultz PG
    Angew Chem Int Ed Engl; 2014 Sep; 53(37):9841-5. PubMed ID: 25056598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
    Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
    J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
    Kovtun Y; Jones GE; Adams S; Harvey L; Audette CA; Wilhelm A; Bai C; Rui L; Laleau R; Liu F; Ab O; Setiady Y; Yoder NC; Goldmacher VS; Chari RVJ; Pinkas J; Chittenden T
    Blood Adv; 2018 Apr; 2(8):848-858. PubMed ID: 29661755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells.
    Zhang H; Luo J; Li Y; Henderson PT; Wang Y; Wachsmann-Hogiu S; Zhao W; Lam KS; Pan CX
    Nanomedicine; 2012 Oct; 8(7):1116-24. PubMed ID: 22197725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia
    Rennert PD; Dufort FJ; Su L; Sanford T; Birt A; Wu L; Lobb RR; Ambrose C
    Mol Cancer Ther; 2021 Oct; 20(10):2071-2081. PubMed ID: 34253594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.
    Zhao X; Singh S; Pardoux C; Zhao J; Hsi ED; Abo A; Korver W
    Haematologica; 2010 Jan; 95(1):71-8. PubMed ID: 19648166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
    Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
    [No Abstract]   [Full Text] [Related]  

  • 20. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
    Lin TY; Zhu Y; Li Y; Zhang H; Ma AH; Long Q; Keck J; Lam KS; Pan CX; Jonas BA
    Nanomedicine; 2019 Aug; 20():102004. PubMed ID: 31055076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.